Parmax Pharma Secures ₹19.28 Crore Funding Amidst Promoter Change

Parmax Pharma will issue 31,37,586 equity shares and 21,45,145 convertible warrants at ₹36.50 each.
Reader Takeaway: Capital infusion for working capital; promoter transition poses execution risks.

What just happened

Parmax Pharma Ltd is set to raise ₹19.28 crore through a preferential issuance of equity shares and convertible warrants. The company plans to issue 31,37,586 equity shares and 21,45,145 warrants, each at an issue price of ₹36.50 per share and warrant. This capital infusion is crucial for the company's working capital requirements and general corporate purposes.

Why this matters

This preferential issue is significant not only for the capital it brings in but also because it will result in a change of promoter control. New investors, including Dhiren Chandulal Shah and Sunil Chinubhai Shah, will acquire control, making them the new promoters. This transition triggers a mandatory open offer for up to 23,46,250 equity shares of the company.

The authorised share capital is also proposed to be increased from ₹6 crore to ₹10 crore to accommodate these changes.

The backstory

This move signifies a new chapter for Parmax Pharma, with a complete overhaul of its ownership structure. The capital raised is earmarked primarily for working capital, with ₹16.39 crore allocated for this purpose over 12-18 months, and ₹2.89 crore for general corporate purposes within six months.

What changes now

Upon the successful completion of the preferential issue and share purchase agreement, the acquirers will become the new promoters. The company's capital structure will also change with the issuance of new shares and warrants. The total outstanding shares are expected to increase to 90,24,031 upon full conversion of warrants.

Risks to watch

The primary risks involve the transition of management and the execution of the deal. The transaction is subject to necessary regulatory approvals from SEBI and compliance with SAST and ICDR regulations. Investors should closely monitor the EGM outcome and the open offer process.

Peer comparison

Information on comparable fund-raising or promoter changes within Parmax Pharma's immediate peers is not readily available from the filing. The company operates in the pharmaceutical sector, where capital raises are common for expansion and working capital needs.

Context metrics (time-bound)

• Total fundraising: ₹19.28 crore.
• Equity Shares issued: 31,37,586.
• Convertible Warrants issued: 21,45,145.
• Issue Price: ₹36.50 per share/warrant.
• Working Capital allocation: ₹16.39 crore (approx. 85% of proceeds).
• General Corporate Purposes allocation: ₹2.89 crore.
• Mandatory Open Offer size: Up to 23,46,250 equity shares.

What to track next

Investors should monitor the upcoming Extraordinary General Meeting (EGM) for shareholder approval, the progress of regulatory clearances, and the details of the mandatory open offer. The effective deployment of the raised capital into working capital will be crucial for the company's operational performance.